Mechanism of Action
Amylin Receptor Activation
Pramlintide activates amylin/" class="wiki-internal-link">amylin receptors (AMY1-3), which are heterodimeric complexes of the calcitonin receptor (CTR) paired with receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3. AMY receptors couple through Gs to increase cAMP. In the brain, AMY1 and AMY3 in the area postrema and nucleus tractus solitarius mediate satiety signaling. In the stomach, amylin receptor activation delays gastric emptying, reducing the rate of glucose delivery to the intestine for absorption.
Postprandial Glucose Control
Pramlintide reduces postprandial glucose through three complementary mechanisms: (1) slowing gastric emptying, reducing the rate of carbohydrate digestion and glucose absorption; (2) suppressing postprandial glucagon secretion from alpha cells (excess glucagon in diabetes contributes significantly to hyperglycemia); and (3) promoting central satiety signals that reduce meal size and caloric intake. Together, these effects lower postprandial glucose without causing direct hypoglycemia (unlike insulin).
Central Satiety Effects
Area postrema AMY receptors project to the nucleus tractus solitarius and hypothalamus, providing satiety signals that reduce meal duration and caloric intake. In obesity models, pramlintide reduces food intake by 20-30% and body weight significantly. Combination with leptin/" class="wiki-internal-link">leptin (which restores leptin sensitivity partially via amylin) produces synergistic weight loss exceeding either agent alone. This led to development of combination amylin-leptin co-agonists for obesity.
Research Summary
Type 1 and Type 2 Diabetes
Standard of CarePhase III trials showed pramlintide reduces HbA1c by ~0.4-0.7% as insulin adjunct with 1-1.5 kg weight reduction versus placebo (which typically gains weight). Postprandial glucose is reduced 40-50 mg/dL. It is FDA-approved for insulin-using type 1 and type 2 patients with suboptimal glycemic control. Adoption has been limited by the requirement to reduce mealtime insulin (to prevent hypoglycemia) and the need for separate injections at each meal.
Obesity
Phase II/IIIPramlintide 240 mcg SC twice daily in obese non-diabetic subjects achieved 6-7% body weight loss over 16 weeks versus 1-2% placebo, modest but meaningful. Combination with metreleptin (leptin analogue) achieved 12-13% weight loss, demonstrating synergy. The amylin-leptin combination triggered development of peptide dual agonists now in clinical trials for obesity.
Amylin-Leptin Synergy
TranslationalA key mechanistic finding is that amylin restores leptin sensitivity in diet-induced obese (DIO) animals, enabling leptin to produce weight loss even in the context of leptin resistance. This sensitization occurs via amylin-mediated STAT3 and mTOR signaling changes in hypothalamic neurons. Cagrilintide (a long-acting amylin analogue in semaglutide combination as CagriSema) is a direct therapeutic descendant of this pramlintide-leptin research.
Calculate your Pramlintide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Type 1 DM adjunct | Start 15 mcg SC pre-meal; titrate to 60 mcg | With each major meal (reduce mealtime insulin 50% at initiation) | SC injection (separate from insulin) |
| Type 2 DM adjunct | Start 60 mcg SC pre-meal; titrate to 120 mcg | With each major meal | SC injection |
| Obesity research | 180-240 mcg SC twice daily | Twice daily between meals | SC injection |
Never mix pramlintide with insulin in the same syringe. Must reduce mealtime insulin 50% when initiating to prevent hypoglycemia. Inject at different site from insulin.
Interactions
Safety Profile
The FDA required a black box warning for severe insulin-induced hypoglycemia risk, the primary serious adverse effect. Nausea is the most common adverse effect (50% at initiation), dose-related, and decreases over weeks. Vomiting and anorexia also occur. Hypoglycemia risk is greatest at initiation when insulin doses have not yet been reduced. No evidence of amyloid-related toxicity (the soluble proline analogue does not aggregate). Long-term use is associated with sustained modest weight loss. Contraindicated in gastroparesis and hypoglycemia unawareness.
References
- [1]Ratner RE, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus. Diabet Med. 2004.
- [2]Ravussin E, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009.
- [3]Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010.